Clinical Trial Update: A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients [Phase 3]

View source ↗

Summary

Phase 3 extension study assessing long-term safety, tolerability and efficacy of PA21 phosphate binder in dialysis patients; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• PA21 (PA21)

Snippet

Sponsor: Vifor Pharma | Conditions: Chronic Kidney Disease Requiring Chronic Dialysis | Phase 3 | Status: COMPLETED | Results posted: 2014-02-17